AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

AstraZeneca PLC

Cash and Cash Equivalents

Cash and Cash Equivalents %Chg

Cash and Cash Equivalents Common Size

Short-Term Investments

Short-Term Investments %Chg

Short-Term Investments Common Size

Total Cash and Cash Equivalents

Total Cash and Cash Equivalents %Chg

Total Cash and Cash Equivalents Common Size

Accounts Receivable

Accounts Receivable %Chg

Accounts Receivable Common Size

Total Trade Receivables

Total Trade Receivables %Chg

Total Trade Receivables Common Size

Inventories

Inventories %Chg

Inventories Common Size

Other Current Assets

Other Current Assets %Chg

Other Current Assets Common Size

Total Current Assets

Total Current Assets %Chg

Total Current Assets Common Size

Net Property, Plant & Equipment

Net Property, Plant & Equipment %Chg

Net Property, Plant & Equipment Common Size

Net Intangible Assets

Net Intangible Assets %Chg

Net Intangible Assets Common Size

Goodwill

Goodwill %Chg

Goodwill Common Size

Long-Term Investments

Long-Term Investments %Chg

Long-Term Investments Common Size

Other Long-Term Assets

Other Long-Term Assets %Chg

Other Long-Term Assets Common Size

Total Assets

Total Assets %Chg

Total Assets Common Size

Accounts Payable

Accounts Payable %Chg

Accounts Payable Common Size

Short-Term Debt

Short-Term Debt %Chg

Short-Term Debt Common Size

Current Portion of Leases

Current Portion of Leases %Chg

Current Portion of Leases Common Size

Other Current Liabilities

Other Current Liabilities %Chg

Other Current Liabilities Common Size

Total Current Liabilities

Total Current Liabilities %Chg

Total Current Liabilities Common Size

Long-Term Debt

Long-Term Debt %Chg

Long-Term Debt Common Size

Leases

Leases %Chg

Leases Common Size

Other Long-Term Liabilities

Other Long-Term Liabilities %Chg

Other Long-Term Liabilities Common Size

Total Long-Term Liabilities

Total Long-Term Liabilities %Chg

Total Long-Term Liabilities Common Size

Total Liabilities

Total Liabilities %Chg

Total Liabilities Common Size

Common Stock

Common Stock %Chg

Common Stock Common Size

Additional Paid-in Capital

Additional Paid-in Capital %Chg

Additional Paid-in Capital Common Size

Accumulated Other Comprehensive Income

Accumulated Other Comprehensive Income %Chg

Accumulated Other Comprehensive Income Common Size

Retained Earnings

Retained Earnings %Chg

Retained Earnings Common Size

Total Common Shareholders' Equity

Total Common Shareholders' Equity %Chg

Total Common Shareholders' Equity Common Size

Minority Interests and Other

Minority Interests and Other %Chg

Minority Interests and Other Common Size

Total Shareholders' Equity

Total Shareholders' Equity %Chg

Total Shareholders' Equity Common Size

Total Liabilities and Shareholders' Equity

Total Liabilities and Shareholders' Equity %Chg

Total Liabilities and Shareholders' Equity Common Size

Revenue

EBIT

EBITDA

CapEx

Net Interest Income

Assets

Adjusted EBITDA

Gross Profit

Adjusted Net Income

Net Revenue

Net Income

Average Assets

Adjusted EBIT

Adjusted Revenue

Adjusted EBT

Adjusted Funds From Operations

Assets	Jun '25	Dec '24	Jun '24	Dec '23	Jun '23	Dec '22
Cash and Cash Equivalents	7,058	5,488	6,916	5,840	5,664	6,166
Short-Term Investments	50	166	160	122	148	239
Total Cash and Cash Equivalents	7,108	5,654	7,076	5,962	5,812	6,405
Accounts Receivable	14,168	12,972	11,047	12,126	11,092	10,521
Total Trade Receivables	14,168	12,972	11,047	12,126	11,092	10,521
Inventories	6,467	5,288	5,667	5,424	5,051	4,699
Other Current Assets	1,196	1,913	1,603	1,542	884	968
Total Current Assets	28,939	25,827	25,393	25,054	22,839	22,593
Net Property, Plant & Equipment	13,229	11,647	10,833	10,502	9,624	9,449
Net Intangible Assets	37,925	37,177	39,426	38,089	38,326	39,307
Goodwill	21,222	21,025	21,060	20,048	19,960	19,820
Long-Term Investments	2,139	1,900	1,871	1,677	1,143	1,142
Other Long-Term Assets	8,968	6,459	5,757	5,749	4,651	4,172
Total Assets	112,422	104,035	104,340	101,119	96,543	96,483

Liabilities	Jun '25	Dec '24	Jun '24	Dec '23	Jun '23	Dec '22
Accounts Payable	23,986	22,465	20,463	22,374	19,738	19,040
Short-Term Debt	6,492	2,337	5,067	5,129	4,556	5,314
Current Portion of Leases	361	339	292	271	231	228
Other Current Liabilities	2,697	2,725	2,744	2,768	1,850	1,711
Total Current Liabilities	33,536	27,866	28,566	30,542	26,375	26,293
Long-Term Debt	24,714	26,506	27,225	22,365	24,329	22,965
Leases	1,272	1,113	949	857	722	725
Other Long-Term Liabilities	8,090	7,679	8,002	8,189	7,701	9,442
Total Long-Term Liabilities	34,076	35,298	36,176	31,411	32,752	33,132
Total Liabilities	67,612	63,164	64,742	61,953	59,127	59,425

Equity	Jun '25	Dec '24	Jun '24	Dec '23	Jun '23	Dec '22
Common Stock	388	388	388	388	387	387
Additional Paid-in Capital	35,238	35,226	35,199	35,789	35,163	35,756
Accumulated Other Comprehensive Income	2,070	2,012	2,078	1,464	2,076	1,468
Retained Earnings	7,023	3,160	1,847	1,502	-234	-574
Total Common Shareholders' Equity	44,719	40,786	39,512	39,143	37,392	37,037
Minority Interests and Other	91	85	86	23	24	21
Total Shareholders' Equity	44,810	40,871	39,598	39,166	37,416	37,058
Total Liabilities and Shareholders' Equity	112,422	104,035	104,340	101,119	96,543	96,483